Recent News

• 04.23.2025 - Alex Thompson
• 04.23.2025 - Alex Thompson
• 03.07.2025 - Oruka Therapeutics Announces Preclinical Data for ORKA-002 at the 2025 American Academy of Dermatology Annual Meeting
• 03.07.2025 - Oruka Therapeutics Announces Preclinical Data for ORKA-002 at the 2025 American Academy of Dermatology Annual Meeting
• 03.06.2025 - Oruka Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update
• 03.06.2025 - Oruka Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update
• 03.04.2025 - TD Cowen 45th Annual Health Care Conference
• 03.04.2025 - TD Cowen 45th Annual Health Care Conference

Recent Filings

• 04.18.2025 - DEF 14A Other definitive proxy statements
• 04.18.2025 - DEFA14A Additional definitive proxy soliciting materials and Rule 14(a)(12) material
• 04.18.2025 - ARS Annual Report to Security Holders
• 03.11.2025 - EFFECT Notice of Effectiveness
• 03.10.2025 - SCHEDULE 13D/A General Statement of Acquisition of Beneficial Ownership
• 03.06.2025 - 10-K Annual report [Section 13 and 15(d), not S-K Item 405]
• 03.06.2025 - S-8 Securities to be offered to employees in employee benefit plans
• 03.06.2025 - POS AM Post-Effective amendments for registration statement
• 02.27.2025 - 4 Statement of changes in beneficial ownership of securities
• 02.27.2025 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors